Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks)

Outcome Description:

Study-emergent adverse events are defined as treatment-emergent adverse events with an onset date on or after the first study drug administration date of this study but not later than 12 weeks (84 days) after last injection. Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.

Outcome Time Frame:

Maximum 164 weeks

Safety Issue:

No

Principal Investigator

UCB Clinical Trial Call Center

Investigator Role:

Study Director

Investigator Affiliation:

+1 877 822 9493 (UCB)

Authority:

Austria: Federal Ministry for Health and Women

Study ID:

C87046

NCT ID:

NCT00333788

Start Date:

October 2006

Completion Date:

April 2010

Related Keywords:

• Crohn's Disease
• Crohn's Disease
• Certolizumab pegol
• CDP870
• Cimzia
• Crohn Disease